Abstract:Hong-yu Tao, Chun-yan Zhao, Ying Wang, Wei-jin Sheng, Yong-su Zhen Laboratory of Oncology, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China Correspondence: Wei-jin Sheng; Yong-su Zhen, Email ; Telomere is a protective structure located at the end of chromosomes of eukaryotes, involved in maintaining the integrity and stability of the genome. Telomeres play an essential role in cancer progression; accordingly, targeting telomere dynamics emerges as an effective approach for the development of cancer therapeutics. Targeting telomere dynamics may work through multifaceted molecular mechanisms; those include the activation of anti-telomerase immune responses, shortening of telomere lengths, induction of telomere dysfunction and constitution of telomerase-responsive drug release systems. In this review, we summarize a wide variety of telomere dynamics-targeted agents in preclinical studies and clinical trials, and reveal their promising therapeutic potential in cancer therapy. As shown, telomere dynamics-active agents are effective as anti-cancer chemotherapeutics and immunotherapeutics. Notably, these agents may display efficacy against cancer stem cells, reducing cancer stem levels. Furthermore, these agents can be integrated with the capability of tumor-specific drug delivery by the constitution of related nanoparticles, antibody drug conjugates and HSA-based drugs. Keywords: telomere dynamics, telomerase, alternative lengthening of telomeres (ALT), cancer therapy Graphical Telomere is a protective structure located at the end of the linear chromosome of eukaryotes, which is made up of tandem repetitive DNA sequences and related proteins. It is essential for maintaining the integrity and stability of the genome. A cancer cell, originated from the aggregates of abnormal mutated cells, is characterized by uncontrollably infinite proliferation, infiltrating into surrounding tissues, further metastasizing to distant organs and ultimately leading to the death of host organisms. 1 Remarkable advances in the field of telomere biology have revealed the paramount importance of telomere in cancer progression. However, slightly different from the general hypothesis, several analyses focused on the correlation of telomere lengths and cancer incidence reported that both longer and shorter telomeres were correlated with cancer development. 2 A systematic analysis of telomere lengths of 18,430 samples covering tumor and normal tissues from 31 types of cancers revealed that 70% of samples displayed shortening telomere lengths in comparison with matched normal tissues and 30% showed elongating telomere lengths. In detail, elongated telomeres existed in testicular germ cell tumors, low grade glioma and sarcoma, whereas cervical cancer, endometrial cancer, uveal melanoma, lymphoma, kidney papillary and kidney chromophobe carcinoma showed shortened telomeres. 3 With the participation of telomerase and alternative lengthening of telomeres (ALT) pathway, longer telomeres indicate more replicative times and provide favorable opportunity for the unlimited proliferation of cancer cells. Meanwhile, shortened telomeres may cause the telomere crisis and genomic instability, which also facilitate tumor progression. 4,5 Thus, instead of merely affecting telomere lengths, seeking versatile mechanisms which refer to targeting telomere dynamics may achieve satisfactory results in cancer therapy. The emerging multifaceted strategy as chemotherapeutic, immunotherapeutic and nanomedicine, includes activating anti-telomerase immune responses, shortening telomere lengths, inducing telomere dysfunction and constituting telomerase-responsive drug release system. In this review, the correlation of telomere dynamics and cancer is illustrated, and current anticancer therapeutics that interfere in telomere dynamics are summarized in detail. Meanwhile, the advantages and disadvantages of those therapeutics and their future directions are also critically discussed to fully exploit their potential in cancer therapy. "Telomere" was originally named by Hermann Muller in 1938, based on the Greek words for "end" (telos) and "part" (meros). He discovered that the free end of chromosomes presented a cap-like structure which made it resistant to X-rays. 6 The human telomere was first sequenced as tandem 5'-TTAGGG-3' repeats in 1988 7 and the same repeated 5'-TTAGGG-3' sequence exists among 91 vertebrate species. 8 As a capping structure at the chromosome termini, telomere consists of tandem repeated 5'-(TTAGGG) n -3' double stranded DNA sequence (15–20 kb in human telomere) with a terminus of G-rich single stranded 3'-overhang (50–200 nucleotide) and a multiprotei -Abstract Truncated-

Assessment of telomere length and factors that contribute to its stability

The telomere length dynamic and methods of its assessment

Techniques for Assessing Telomere Length: A Methodological Review

Telomeres and Telomere Length: A General Overview

Telomere Length: A Review of Methods for Measurement

The advancement of telomere quantification methods

Targeting Telomere Dynamics as an Effective Approach for the Development of Cancer Therapeutics

Telomere Length Dynamics and the Evolution of Cancer Genome Architecture

Telomere length: how the length makes a difference

Revisiting Telomere Shortening in Cancer

Telomeres-Structure, Function, And Regulation

Telomere length measurement—Caveats and a critical assessment of the available technologies and tools

Progress in the Study of Telomere and Telomerase

Telomere length in reproduction

Telomere instability and cancer

Telomere length assessment: biomarker of chronic oxidative stress?

Experimental and Computational Approaches to Measure Telomere Length: Recent Advances and Future Directions

Human telomere length is chromosome specific and conserved across individuals

This is a Title in Title Case: Prediction of CML Evolution by Telomere Length Analysis at the Single-Chromosome Level

Role of the ESCRT Complexes in Telomere Biology